Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Sees “Moderate” Namenda Growth Opportunity In Mild Alzheimer’s

Executive Summary

Forest expects approval of its Namenda sNDA for the treatment of mild-to-moderate Alzheimer's disease to generate a "modest uptick" in prescription volume in the second half of the year

You may also be interested in...



Ortho McNeil Neurologics To Promote Razadyne (Formerly Reminyl)

Johnson & Johnson is changing the name of Reminyl (galantamine) to Razadyne in advance of the launch of an extended-release version of the Alzheimer's product

Forest Namenda Has 10% Off-Label Use In Mild-To-Moderate Alzheimer’s

Forest's Alzheimer's disease agent Namenda has 10% off-label use based on early launch data

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS045708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel